These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 19861435)

  • 1. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
    Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
    Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.
    Enkner F; Pichlhöfer B; Zaharie AT; Krunic M; Holper TM; Janik S; Moser B; Schlangen K; Neudert B; Walter K; Migschitz B; Müllauer L
    Pathol Oncol Res; 2017 Jul; 23(3):551-564. PubMed ID: 27844328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of advanced thymic malignancies.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymic tumors: relevant molecular data in the clinic.
    Girard N
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
    Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
    Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
    Girard N; Basse C; Schrock A; Ramkissoon S; Killian K; Ross JS
    Oncologist; 2022 Nov; 27(11):919-929. PubMed ID: 35749302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent genetic aberrations in thymoma and thymic carcinoma.
    Zettl A; Ströbel P; Wagner K; Katzenberger T; Ott G; Rosenwald A; Peters K; Krein A; Semik M; Müller-Hermelink HK; Marx A
    Am J Pathol; 2000 Jul; 157(1):257-66. PubMed ID: 10880395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and mutational status of c-kit in thymic epithelial tumors.
    Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
    J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymoma versus thymic carcinoma: differences in biology impacting treatment.
    Kelly RJ
    J Natl Compr Canc Netw; 2013 May; 11(5):577-83. PubMed ID: 23667207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
    Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
    Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
    Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers for patients with thymic malignancies: not feasible at present?
    Avci N; Cecener G; Deligonul A; Erturk E; Tunca B; Egeli U; Tezcan G; Akyildiz EU; Bayram AS; Gebitekin C; Kurt E; Evrensel T
    Asian Pac J Cancer Prev; 2014; 15(8):3457-60. PubMed ID: 24870739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
    Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
    Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
    Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
    J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 upregulation in thymomas and thymic carcinomas.
    Rieker RJ; Joos S; Mechtersheimer G; Blaeker H; Schnabel PA; Morresi-Hauf A; Hecker E; Thomas M; Dienemann H; Schirmacher P; Kern MA
    Int J Cancer; 2006 Nov; 119(9):2063-70. PubMed ID: 16823844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of proteasome subunit β5t in thymic epithelial tumors.
    Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
    Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
    Pan CC; Chen PC; Chiang H
    J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.